Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients.
Cariti C, Dapavo P, Mastorino L, Ortoncelli M, Siliquini N, Merli M, Avallone G, Giordano S, Fabrizio R, Susca S, Verrone A, Stroppiana E, Quaglino P, Ribero S. Cariti C, et al. Among authors: susca s. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e233-e235. doi: 10.1111/jdv.17766. Epub 2021 Nov 7. J Eur Acad Dermatol Venereol. 2022. PMID: 34672026 No abstract available.
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients.
Mastorino L, Castelli F, Stroppiana E, Verrone A, Ortoncelli M, Susca S, Boskovic S, Passerini SG, Macagno N, Cariti C, Licciardello M, Solaroli C, Pertusi G, Aragone MG, Baggini G, Addese C, Leporati C, Peila R, Giura MT, Rossotto G, Pella P, Mocci L, Merlo G, Tiberio R, Graziola F, Quaglino P, Dapavo P, Ribero S. Mastorino L, et al. Among authors: susca s. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e838-e841. doi: 10.1111/jdv.18314. Epub 2022 Jun 22. J Eur Acad Dermatol Venereol. 2022. PMID: 35686942 No abstract available.
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.
Mastorino L, Cariti C, Susca S, Sciamarrelli N, Borriello S, Ortoncelli M, Stroppiana E, Verrone A, Dapavo P, Quaglino P, Ribero S. Mastorino L, et al. Among authors: susca s. Dermatol Ther. 2022 Nov;35(11):e15818. doi: 10.1111/dth.15818. Epub 2022 Sep 22. Dermatol Ther. 2022. PMID: 36097346 No abstract available.
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
Roccuzzo G, Mastorino L, Susca S, Cariti C, Passerini SG, Sciamarrelli N, Borriello S, Macagno N, Sliquini N, Avallone G, Verrone A, Stroppiana E, Quaglino P, Ortoncelli M, Dapavo P, Ribero S. Roccuzzo G, et al. Among authors: susca s. Clin Exp Dermatol. 2023 Mar 22;48(4):379-381. doi: 10.1093/ced/llac098. Clin Exp Dermatol. 2023. PMID: 36745578 No abstract available.
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. Mastorino L, et al. Among authors: susca s. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1848-1853. doi: 10.1111/jdv.19135. Epub 2023 May 4. J Eur Acad Dermatol Venereol. 2023. PMID: 37113043
17 results